At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed ovarian epithelial or peritoneal cavity cancer
- ✓Relapsed or refractory disease after prior first-line platinum-containing regimen
- ✓Platinum-sensitive or platinum-resistant disease (resistance defined as relapsed/progressive disease within 6 months of platinum completion)
- ✓Measurable or evaluable disease (CA-125 >70 U/mL with doubling from baseline or other evidence of progressive disease)
- ✕Prior gemcitabine or docetaxel therapy
- ✕More than 1 prior chemotherapy regimen (first-line platinum plus consolidation in complete response counts as 1 regimen)
- ✕Peripheral neuropathy >grade 1
- ✕Congestive heart failure, second/third degree heart block, or myocardial infarction within 3 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Gemcitabine hydrochloride for Ovarian Cancer and Peritoneal Cavity Cancer. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with relapsed or refractory ovarian epithelial or peritoneal cancer.
Study Details
Timeline
Interventions
40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days